3 completed, 1 active not recruiting, 1 enrolling by invitation, 1 recruiting. 4 Phase 2, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 3, Active not recruiting 1 |
| Phase 1 | 3 | Completed 2, Active not recruiting 1 |
Follow Melanoma Stage III or IV: new trials by email Literature Review of Melanoma Stage III or IV trials Research Report on Melanoma Stage III or IV
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| CARDiac Toxicity Following ImmunOtherapy Treatment for Melanoma 12-Lead ECG, Transthoracic Echocardiogram, Cardiac MRI - Melanoma Stage III or IV | Enrolling by invitation | Royal Marsden NHS Foundation Trust | 60 | 2025-09-26 | 2025-10-01 | |
| Different Doses of BI-1607 in Combination With Pembrolizumab and Ipilimumab, in Participants With Unresectable or Metastatic Melanoma pembrolizumab (KEYTRUDA®), BI-1607, Ipilimumab (YervoyTM, 50 mg/10 mL solution) - Melanoma Metastatic, Melanoma of Skin | Phase 1 / Phase 2 | Active not recruiting | BioInvent International AB | 35 | 2024-12-11 | 2026-10-02 |
| Observational Study of Patients With Advanced Melanoma (Skin Cancer) to Assess if IOpener®-Melanoma Test Can Predict Response to Immunotherapy. PBMC Kinase Activity Profile - Melanoma Metastatic, Melanoma, Skin | Recruiting | Pamgene International B.V. | 196 | 2024-07-12 | 2025-02-28 | |
| Monocentric Pilot Study Investigating the Metabolic Activity of Melanoma in Vivo During Sorafenib and Dacarbazine Sorafenib (Nexavar), Dacarbazine (DTIC) - Melanoma Stage III or IV, No Prior Chemotherapy | Phase 2 | Completed | University of Zurich | 12 | 2008-12-01 | 2010-01-08 |
| Peptide-pulsed vs. RNA-transfected Dendritic Cell Vaccines in Melanoma Patients autologous dendritic cell vaccine - Melanoma Stage III or IV | Phase 1 / Phase 2 | Completed | Radboud University Medical Center | 64 | 2004-04-01 | 2009-09-29 |
| Dendritic Cell Vaccination in Melanoma Patients Scheduled for Regional Lymph Node Dissection Peptide-pulsed dendritic cells - Melanoma Stage III or IV | Phase 1 / Phase 2 | Completed | Radboud University Medical Center | 40 | 1999-09-01 | 2009-02-19 |
Melanoma (6) · Cardiotoxicity (1) · Neoplasm Metastasis (1) · Uveal Melanoma (1)
Neoplasms (6) · Neoplasms by Histologic Type (6) · Neoplasms by Site (6) · Neoplasms, Germ Cell and Embryonal (6) · Neoplasms, Nerve Tissue (6) · Neuroectodermal Tumors (6) · Neuroendocrine Tumors (6) · Nevi and Melanomas (6) · Skin Diseases (6) · Skin Neoplasms (6) · Skin and Connective Tissue Diseases (6) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Cardiovascular Diseases (1) · Chemically-Induced Disorders (1)
Dacarbazine (1) · Echocardiography (1) · Electrocardiography (1) · Ipilimumab (1) · Solutions (1) · Sorafenib (1) · pembrolizumab (1)
Radboud University Medical Center (2) · BioInvent International AB (1) · Pamgene International B.V. (1) · Royal Marsden NHS Foundation Trust (1) · University of Zurich (1)
Germany (2) · Netherlands (2) · United Kingdom (2) · Spain (1) · Switzerland (1)
Prof. C.G. Figdor, PhD (1) · Prof. G.J. Adema, PhD (1) · Reinhard Dummer, MD (1)